Please assess the completion status of the following clinical trial:

Trial Title: L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient's written informed consent~2. Received a single lung, bilateral lung or heart/lung transplantation between 6 weeks and 26 weeks prior to first IMP administration.~3. Male or female, 18 years of age~4. Capable of self-administration of medications~5. Capable of understanding the purpose and risk of the clinical trial~6. Received the following immunosuppressive agents and dosages for maintenance therapy:~   1. Tacrolimus and~  2. Mycophenolate mofetil (MMF) 1 to 3 g/day and~  3. Prednisone or any other steroid therapy; tapered down~7. Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration.~8. Estimated life expectancy \> 6 month~Exclusion Criteria:~1. Any previous episode of bronchiolitis obliterans (BO) or bronchiolitis obliterans syndrome (BOS) of grade 1 or higher~2. Any active invasive bacterial, viral or fungal infection~3. Received systemic maintenance immunosuppressive therapy other than listed in the inclusion criteria~4. Received any systemic or topical ciclosporin A within~5. Received any systemic or topical Rosuvastatin~6. Current mechanical ventilation~7. Received a lung re-transplantation~8. Pregnant or breast feeding woman~9. Has known hypersensitivity to ciclosporin A~10. Has a serum creatinine value of more than 265 µmol/L (3 mg/dL)~11. Unlikely to comply with visits, inhalation procedures or spirometric measurements~12. Receipt of an investigational drug within 4 weeks prior to first administration of IMP~13. Any co-existing medical condition that in the investigator's judgement~14. Psychiatric disorders or altered mental status~15. Patient was previously enrolled in the present clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-CsA (Type: ACTIVE_COMPARATOR): Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
- L-CsA placebo (Type: PLACEBO_COMPARATOR): Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).